This month marks the start of a new era for GlaxoSmithKline, with Emma Walmsley taking over from Sir Andrew Witty – and big pharma's first female CEO has said she is prepared to make tough ...

The results will be welcomed by boss Emma Walmsley (pictured), who has been trying to improve the pipeline of new drugs and ...

As Dame Emma Walmsley stood up to deliver GSK’s latest ... research by regulators in the US and EU, as well as other ...

Walmsley, the only woman CEO of a major pharma company, told Fortune at the time that GSK was working on building its vaccine portfolio. That’s not the only avenue where GSK is growing.

Five years into her transformation-focused tenure, Walmsley says the global drugmaker is at last ready to deliver results. She completed the final step of that overhaul this summer, spinning off ...

GlaxoSmithKline’s new CEO Emma Walmsley is set to outline her vision for the company alongside half-year results next month – but reports suggest that she may shake up the consumer products ...

CEO Emma Walmsley says. Speaking at the CEO Times Summit in London, Walmsley highlights the U.K. pharmaceutical company's refocused R&D strategy, with investments concentrated in the U.K., U.S ...

Emma Walmsley needs to convince shareholders she has the right plan. The boss of GlaxoSmithKline faces one of the biggest challenges of her career as she tries to convince shareholders in the ...

It’s been a big year for Emma Walmsley (pictured above), chief executive of Britain’s biggest drugmaker GSK. She was nominated to the board of tech giant Microsoft. She was named as one of the most ...